Citizens JMP reiterates Option Care Health stock rating on industry scale

Citizens JMP reiterated its Market Outperform rating and $36 price target on Option Care Health (OPCH), citing the company's industry-leading scale, strong cash flows, and potential for continued share gains; this positive outlook is supported by recent Q1 2025 results, which saw a 16% year-over-year revenue increase to $1.33 billion and EPS of $0.40, both exceeding expectations, while UBS also upgraded OPCH to Buy with a $40 target, noting potential benefits from the shift towards home care despite a projected $60-70 million gross profit headwind from STELARA.

Analysis

Citizens JMP reiterated its Market Outperform rating and $36.00 price target for Option Care Health (OPCH), representing a valuation of 14.5 times the company’s expected 2025 adjusted EBITDA. This positive stance is underpinned by OPCH's "industry-leading scale," expectations for "continued share gains," and "longer-term SG&A leverage." The company's financial health is demonstrated by 17% revenue growth and a 20% gross profit margin in the last twelve months, coupled with "strong cash flows" evidenced by significant share buybacks and a 7% free cash flow yield. Option Care Health's first-quarter 2025 results further support this optimism, with revenue increasing 16% year-over-year to $1.33 billion and earnings per share (EPS) of $0.40, both surpassing analyst forecasts. This revenue growth was driven by both acute and chronic therapies, particularly strong performance in rare and limited distribution therapies. First-quarter gross profit rose 10% to $263.1 million, and adjusted EBITDA increased 14% to $111.8 million, also exceeding estimates. Reinforcing the positive sentiment, UBS upgraded OPCH from Neutral to Buy, raising its price target to $40.00, citing strong earnings momentum and the potential benefits from a broader healthcare shift towards home care, despite an anticipated $60-70 million full-year gross profit headwind from the drug STELARA. InvestingPro data suggests the stock is slightly undervalued, with analyst targets ranging from $34 to $41. Strategic initiatives, including acquisitions and the opening of new infusion clinics, are poised to support future growth.

Key Decisions for Investors

• Investors may consider OPCH a potentially undervalued opportunity given the strong Q1 2025 performance, positive analyst ratings, and InvestingPro's Fair Value assessment, alongside a robust free cash flow yield.
• Monitor the company's ability to mitigate the $60-70 million gross profit headwind from STELARA through volume growth, particularly from the shift to home care, and successful execution of its strategic initiatives.
• Closely track progress on achieving longer-term SG&A leverage and continued market share gains, as these are key drivers for the reiterated 'Market Outperform' thesis.
• Evaluate the impact of ongoing strategic partnerships, acquisitions, and new clinic openings on sustaining revenue growth and enhancing market presence in the evolving healthcare services landscape.